NR 577 Week 6 Cardiovascular Risk Assessment Example

Risk Assessment Write-Up: A 10-Year Cardiovascular Risk Estimate of 6.0% for a 44-Year-Old With New Type 2 Diabetes, Its Inputs and Sources, and What It Changes About a Statin

Student Name

College of Nursing, Chamberlain University

NR 577: Primary Care Management of Adolescents and Adults

Instructor Name

Month Day, Year

Risk Assessment Write-Up: A 10-Year Cardiovascular Risk Estimate of 6.0% for a 44-Year-Old With New Type 2 Diabetes, Its Inputs and Sources, and What It Changes About a Statin

The Question

Whether a 44-year-old with type 2 diabetes, diagnosed four weeks ago after recommended screening (Davidson et al., 2021), should be offered a statin, and if so at what intensity. A risk estimate is part of that decision, but in this case it is not the whole of it, because the diagnosis itself places the patient in a group the cholesterol guideline addresses directly.

Inputs, as Entered

Table 1

Inputs to the Pooled Cohort Equations, With Their Sources and Dates

Each input was checked for age. The lipid values are five weeks old and nonfasting, which is acceptable for risk estimation. The systolic pressure is a home average rather than a single office reading, which is a better estimate of usual pressure.

The Tool and the Output

The pooled cohort equations, which the 2018 cholesterol guideline uses for adults aged 40 to 75 (Grundy et al., 2019). Output: 6.0% estimated risk of a first heart attack, stroke or cardiovascular death over the next 10 years, which the guideline describes as borderline, between 5% and 7.5%.

In absolute terms: of 100 people like this patient, about 6 would be expected to have a heart attack or stroke in the next 10 years, and 94 would not.

Checking the Calculation

The estimate was calculated twice, once in the clinic's record system and once by hand with the published coefficients for the equations, because a mistyped input changes the output without any warning. Both gave 6.0%. I then changed one input at a time to see how sensitive the estimate was: with a systolic pressure of 146 instead of 136 the estimate rose to about 6.6%, and with an HDL of 45 instead of 38 it fell to about 5.2%. The estimate is therefore borderline whichever reasonable value is used, which supports the guideline's reliance on the diagnosis rather than the number.

Limits of the Tool for This Patient

The equations were derived in older cohorts, and they are known to overestimate risk in some contemporary populations. The American Heart Association's newer PREVENT equations were developed in larger, more recent cohorts and add kidney function and, optionally, other measures (Khan et al., 2024); they were not used here because the practice's guideline-based pathway still uses the pooled cohort equations, but their existence is a reason not to treat 6.0% as precise. The equations also do not include family history; this patient's father had a heart attack at 61, which the guideline counts as a risk-enhancing factor if it occurred before 55 in a male first-degree relative. At 61, it does not meet that definition, so it is noted but not counted.

What the Number Changes, and What It Does Not

For adults aged 40 to 75 with diabetes, the cholesterol guideline recommends a moderate-intensity statin regardless of the calculated 10-year risk (Grundy et al., 2019). So the estimate does not decide whether to offer a statin; the diagnosis does. What the estimate does change is intensity and urgency. At 6.0%, with no other diabetes-specific risk enhancers yet identified, a moderate-intensity statin is the recommendation, not a high-intensity one. If the urine albumin result comes back raised, or if the patient later develops other risk enhancers, a higher intensity would be considered.

Recommendation: offer atorvastatin at a moderate dose, discussed at the next visit, with the decision the patient's.

Other Risk-Enhancing Factors Reviewed

The guideline lists factors that can move a borderline estimate toward treatment. For this patient: the father's heart attack at 61 does not meet the definition of premature disease in a male relative, which is before 55. The LDL cholesterol, calculated at 142 mg/dL, is below the 160 that counts as an enhancer. No chronic kidney disease is known; the urine albumin result is pending. No inflammatory disease. Waist circumference was 104 cm, which, with the low HDL and high-normal triglycerides, is close to the metabolic syndrome, itself listed as an enhancer. So one possible enhancer may apply, and one result is still awaited.

Why Not Wait for the Urine Albumin

The guideline's statin advice for diabetic adults aged 40 through 75 does not depend on the urine albumin, so there is no reason to delay the conversation until the result is back. The albumin result could raise the intensity, but it cannot remove the recommendation. Waiting would add a visit without changing the first decision, and for a patient whose visits cost sleep, an unnecessary visit has a real cost.

Explaining the Number to the Patient

I plan to say: "Out of 100 people with your numbers, about 6 would go on to a heart attack or a stroke within 10 years. A statin would bring that down to about 4 or 5. Because you now have diabetes, the guidelines suggest a statin for almost everyone your age, but whether to take it is your call." I will avoid describing the risk only as a relative reduction, since a 25% to 30% relative reduction sounds larger than a change from 6 in 100 to about 4 or 5 in 100.

How the Patient Responded

The patient asked whether 6 in 100 was high. I said it was neither high nor low for someone of 44, but that having diabetes was the main reason the guidelines suggested a statin. The patient said, "So it's the diabetes, not the number," which was the correct summary, and asked for a week to think. That request is recorded, and the statin will be discussed again at the telehealth visit, with the albumin result in hand by then.

What Remains Uncertain

The urine albumin result is pending. The PREVENT estimate was not calculated. And the patient's work, which involves heavy lifting all night, may make the patient fitter than the equations assume, a factor no current tool captures.

References

Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Krist, A. H., Kubik, M., Li, L., Ogedegbe, G., Owens, D. K., Pbert, L., Silverstein, M., Stevermer, J., Tseng, C.-W., & Wong, J. B. (2021). Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. JAMA, 326(8), 736-743. https://doi.org/10.1001/jama.2021.12531

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., . . . Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625

Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., Blaha, M. J., Carson, A. P., Chang, A. R., Ciemins, E., Go, A. S., Gutierrez, O. M., Hwang, S.-J., Jassal, S. K., Kovesdy, C. P., Lloyd-Jones, D. M., Shlipak, M. G., Palaniappan, L. P., Sperling, L., . . . Coresh, J. (2024). Development and validation of the American Heart Association's PREVENT equations. Circulation, 149(6), 430-449. https://doi.org/10.1161/CIRCULATIONAHA.123.067626